Johnson & Johnson delays vaccine rollout in Europe amid blood clots probe in US

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"2">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Johnson &amp&semi; Johnson has said it is delaying the rollout of its coronavirus vaccine in Europe amid a US probe into rare blood clots&period;<&sol;p>&NewLine;<p>The company announced the decision on Tuesday after regulators in the United States said they were recommending a &OpenCurlyDoubleQuote;pause” in administration of the single-dose vaccine to investigate reports of potentially dangerous blood clots&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We have been reviewing these cases with European health authorities&comma;” the company said&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We have made the decision to proactively delay the rollout of our vaccine in Europe&period;”<&sol;p>&NewLine;<p>It comes after the US Centres for Disease Control and Prevention &lpar;CDC&rpar; and the Food and Drug Administration &lpar;FDA&rpar; issued a joint statement saying they were investigating unusual clots in six women that occurred six to 13 days after vaccination&period;<&sol;p>&NewLine;<figure id&equals;"attachment&lowbar;167538" aria-describedby&equals;"caption-attachment-167538" style&equals;"width&colon; 598px" class&equals;"wp-caption aligncenter"><img src&equals;"https&colon;&sol;&sol;londonglossy&period;com&sol;wp-content&sol;uploads&sol;2021&sol;04&sol;5FC847DA-9FB0-47B2-BC11-F4CED38407A6&period;jpeg" alt&equals;"" width&equals;"598" height&equals;"293" class&equals;"size-full wp-image-167538" &sol;><figcaption id&equals;"caption-attachment-167538" class&equals;"wp-caption-text">Boxes of Janssen vaccines<&sol;figcaption><&sol;figure>&NewLine;<p>The clots occurred in veins that drain blood from the brain and occurred together with low platelets&period;<&sol;p>&NewLine;<p>All six cases were in women between the ages of 18 and 48&period;<&sol;p>&NewLine;<p>The reports appear similar to a rare&comma; unusual type of clotting disorder that European authorities say is possibly linked to another Covid-19 vaccine not yet cleared in the US&comma; from AstraZeneca&period;<&sol;p>&NewLine;<p>The delay is a further blow to vaccination drives in European Union member nations&comma; which have been plagued by supply shortages&comma; logistical problems and concerns over unusual blood clots in a small number of people who received the AstraZeneca vaccine&period;<&sol;p>&NewLine;<p><&excl;--Ads1--><&sol;p>&NewLine;<p>The blood clot reports prompted several countries in the 27-nation bloc to limit the AstraZeneca vaccine to older age groups&comma; who are more at risk from serious illness when infected with Covid-19&period;<&sol;p>&NewLine;<p>The European Medicines Agency &lpar;EMA&rpar;&comma; the EU’s equivalent to the FDA&comma; said last Friday that it was reviewing cases reported in the United States of blood clotting in people who had received the Johnson &amp&semi; Johnson vaccine&comma; which was developed by the company’s Janssen subsidiary&period;<&sol;p>&NewLine;<p>The Amsterdam-based EMA said following the US announcement on Tuesday that it &OpenCurlyDoubleQuote;is currently not clear whether there is a causal association between vaccination with Covid-19 Vaccine Janssen and these conditions”&period;<&sol;p>&NewLine;<p>The European agency’s safety committee &OpenCurlyDoubleQuote;is investigating these cases and will decide whether regulatory action may be necessary”&comma; the EMA said in an email to the Associated Press&period;<&sol;p>&NewLine;<p>The EU ordered 200 million doses of the Johnson &amp&semi; Johnson vaccine in 2021&period;<&sol;p>&NewLine;<p>Britain ordered 30 million doses of the J&amp&semi; J vaccine&comma; though UK regulators have not yet approved its use&period;<&sol;p>&NewLine;<p>Officials in Germany&comma; which was due to receive 232&comma;800 doses of the vaccine this week and 10&period;1 million doses by the end of June&comma; said earlier on Tuesday that there were no immediate plans to change the schedule&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;I don’t currently have the date from which Johnson &amp&semi; Johnson will be administered&comma;” Health Ministry spokesman Hanno Kautz told reporters in Berlin&period;<&sol;p>&NewLine;<p><&excl;--Ads2--><&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;But in principle&comma; we naturally always take such warnings in an international context seriously and investigate them&period;”<&sol;p>&NewLine;<p>Italy also expected to receive its first Johnson &amp&semi; Johnson deliveries this week&period;<&sol;p>&NewLine;<p>The Lazio region surrounding Rome planned to give the prison population the single jab&comma; while the northern Veneto region&comma; which includes Venice&comma; planned to use it for housebound adults over 80&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;I am watching today’s news with concern&comma; as a humanitarian actor&period; I am also watching with satisfaction&comma; because the regulatory system is working&comma;” Francesco Rocca&comma; president of the International Federation of the Red Cross&comma; told foreign reporters in Italy&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;I imagine there will be repercussions&comma; as we are waiting for millions of doses&period; But this means the controls are working&period; If we need to be prudent&comma; we need to be prudent&period;”<&sol;p>&NewLine;<p><&excl;--Ads3--><&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ed2a9f1f80e">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ed2a9f1f80e'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version